Serotonin reuptake inhibitors in pregnancy: Can genes help us in predicting neonatal adverse outcome?

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Giudici, Valentina ^a   Pogliani, Laura ^a   Cattaneo, Dario ^a   Dilillo, Dario ^a   Zuccotti, Gian Vincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

DRUG EFFECTS; FEMALE; FETUS; HUMAN; NEWBORN; PHARMACOGENETICS; PREGNANCY; PREGNANCY OUTCOME;

FEMALE; FETUS; HUMANS; INFANT, NEWBORN; PHARMACOGENETICS; PREGNANCY; PREGNANCY OUTCOME; SEROTONIN UPTAKE INHIBITORS;

EID: 84893718898     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/276918     Document Type: Review

References (29)

1. Marcus S. M., Flynn H. A., Blow F. C., Barry K. L., Depressive symptoms among pregnant women screened in obstetrics settings. Journal of Women's Health 2003 12 4 373 380 2-s2.0-0037498595 (Pubitemid 36701614)
2. Andersson L., Sundström-Poromaa I., Bixo M., Wulff M., Bondestam K., Åström M., Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. The American Journal of Obstetrics and Gynecology 2003 189 1 148 154 2-s2.0-0038675045 10.1067/mob.2003.336 (Pubitemid 36886540)
3. Yonkers K. A., Wisner K. L., Stewart D. E., Oberlander T. F., Dell D. L., Stotland N., Ramin S., Chaudron L., Lockwood C., The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. General Hospital Psychiatry 2009 31 5 403 413 2-s2.0-69049099828 10.1016/j.genhosppsych.2009.04.003
4. National Institute for Clinical Excellence, NICE antenatal and postnatal mental health. 2007
5. Bellantuono C., Migliarese G., Gentile S., Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Human Psychopharmacology 2007 22 3 121 128 2-s2.0-34248327959 10.1002/hup.836 (Pubitemid 46730580)
6. Kievet N., Dolman K., Honig A., The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatric Disease and Treatment 2013 9 1257 1266
7. Boucher N., Bairam A., Beaulac-Baillargeon L., A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. Journal of Clinical Psychopharmacology 2008 28 3 334 339 2-s2.0-51449106586 10.1097/JCP.0b013e318173aa2e
8. Oberlander T. F., Warburton W., Misri S., Aghajanian J., Hertzman C., Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Archives of General Psychiatry 2006 63 8 898 906 2-s2.0-33746869251 10.1001/archpsyc.63.8.898 (Pubitemid 44188483)
9. Klinger G., Merlob P., Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Israel Journal of Psychiatry and Related Sciences 2008 45 2 107 113 2-s2.0-49949087415
10. Hudak M. L., Tan RC neonatal drug withdrawal. Pediatrics 2012 129 2 e540 e560
11. Sie S. D., Wennink J. M. B., van Driel J. J., te Winke A. G. W., Boer K., Casteelen G., van Weissenbruch M. M., Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Archives of Disease in Childhood 2012 97 6 F472 F476 2-s2.0-79960655191 10.1136/adc.2011.214239
12. Oberlander T. F., Misri S., Fitzgerald C. E., Kostaras X., Rurak D., Riggs W., Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Journal of Clinical Psychiatry 2004 65 2 230 237 2-s2.0-1842866929 10.4088/JCP.v65n0214
13. Sanz E. J., De-las-Cuevas C., Kiuru A., Bate A., Edwards R., Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. The Lancet 2005 365 9458 482 487 2-s2.0-13444252680 10.1016/S0140-6736(05)17865-9 (Pubitemid 40215730)
14. Moses-Kolko E. L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., Wisner K. L., Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. Journal of the American Medical Association 2005 293 19 2372 2383 2-s2.0-18644382386 10.1001/jama.293.19.2372 (Pubitemid 40676760)
15. Laine K., Heikkinen T., Ekblad U., Kero P., Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Archives of General Psychiatry 2003 60 7 720 726 2-s2.0-0038354618 10.1001/archpsyc.60.7.720 (Pubitemid 36818634)
16. Heikkinen T., Ekblad U., Palo P., Laine K., Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clinical Pharmacology and Therapeutics 2003 73 4 330 337 2-s2.0-0037384041 10.1016/S0009-9236(02) 17634-X (Pubitemid 36403593)
17. Costei A. M., Kozer E., Ho T., Ito S., Koren G., Perinatal outcome following third trimester exposure to paroxetine. Archives of Pediatrics and Adolescent Medicine 2002 156 11 1129 1132 2-s2.0-0036873248 (Pubitemid 36343460)
18. Pollock B. G., Ferrell R. E., Mulsant B. H., Mazumdar S., Miller M., Sweet R. A., Davis S., Kirshner M. A., Houck P. R., Stack J. A., Reynolds C. F. III, Kupfer D. J., Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000 23 5 587 590 2-s2.0-0033807374 10.1016/S0893- 133X(00)00132-9
19. Oberlander T. F., Bonaguro R. J., Misri S., Papsdorf M., Ross C. J. D., Simpson E. M., Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Molecular Psychiatry 2008 13 1 65 73 2-s2.0-37249031342 10.1038/sj.mp.4002007 (Pubitemid 350275180)
20. Laine K., Kytölä J., Bertilsson L., Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Therapeutic Drug Monitoring 2004 26 6 685 687 2-s2.0-9644275322 10.1097/00007691-200412000-00016 (Pubitemid 39579152)
21. Stiskal J. A., Defective alleles may not have contributed to adverse effects. Therapeutic Drug Monitoring 2006 28 1 142 2-s2.0-33745514795 10.1097/01.ftd.0000167888.70645.83 (Pubitemid 44391711)
22. Hilli J., Heikkinen T., Rontu R., Lehtimäki T., Kishida I., Aklillu E., Bertilsson L., Vahlberg T., Laine K., MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. European Neuropsychopharmacology 2009 19 5 363 370 2-s2.0-63149182590 10.1016/j.euroneuro.2009.01.006
23. Hutson J. R., Koren G., Matthews S. G., Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology. Placenta 2010 31 5 351 357 2-s2.0-77951977594 10.1016/j.placenta.2010.02.010
24. Kato M., Fukuda T., Serretti A., Wakeno M., Okugawa G., Ikenaga Y., Hosoi Y., Takekita Y., Mandelli L., Azuma J., Kinoshita T., ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008 32 2 398 404 2-s2.0-38749113409 10.1016/j.pnpbp.2007.09.003 (Pubitemid 351178955)
25. de Klerk O. L., Nolte I. M., Bet P. M., Bosker F. J., Snieder H., den Boer J. A., Bruggeman R., Hoogendijk W. J., Penninx B. W., ABCB1 gene variants influence tolerance to selectiveserotonin reuptake inhibitors in a large sample of Dutch cases with majordepressive disorder. The Pharmacogenomics Journal 2013 13 4 349 353
26. Berle J. Ø., Spigset O., Antidepressant use during breastfeeding. Current Women's Health Reviews 2011 7 1 28 34 2-s2.0-79551644977 10.2174/157340411794474784
27. Berle J. Ø., Steen V. M., Aamo T. O., Breilid H., Zahlsen K., Spigset O., Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. Journal of Clinical Psychiatry 2004 65 9 1228 1234 2-s2.0-5444248599 10.4088/JCP.v65n0911
28. Ververs F. F. T., Voorbij H. A. M., Zwarts P., Belitser S. V., Egberts T. C. G., Visser G. H. A., Schobben A. F. A. M., Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clinical Pharmacokinetics 2009 48 10 677 683 2-s2.0-70349094422 10.2165/11318050- 000000000-00000
29. Matsui D. M., Therapeutic drug monitoring in pregnancy. Therapeutic Drug Monitoring 2012 34 507 511